StockNews.com started coverage on shares of iBio (NYSE:IBIO – Free Report) in a research note released on Friday morning. The firm issued a sell rating on the stock.
iBio Stock Performance
IBIO stock opened at $2.02 on Friday. iBio has a 12 month low of $1.02 and a 12 month high of $28.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91.
iBio (NYSE:IBIO – Get Free Report) last announced its quarterly earnings data on Friday, February 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- Insider Trades May Not Tell You What You Think
- 5 Trends You Need to Know This Quarter
- What is the S&P/TSX Index?
- MarketBeat Week in Review – 4/8 – 4/12
- How to Capture the Benefits of Dividend Increases
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
